NUCLEOLIN and cancer: Thus, as ceramides have been reported to inhibit the PI3k/Akt pathway [39], it was then questioned whether the mechanism remains the same upon intracellular delivery mediated by the F3 peptide/nucleolin system into cancer cells with different basal levels of phosphorylated/active Akt.